Recall notices have caused huge shifts in other device makers’ stocks.
San Clemente’s Glaukos Corp. (NYSE: GKOS), a maker of stents inserted into the eye to treat the effects of glaucoma, saw its stock surge nearly 50% in a matter of days last year after a competitor voluntarily recalled a similar product. It’s currently valued at about $2.3 billion.
Shares of Edwards Lifesciences Corp. (NYSE: EW), slid about 3% to around $215 each following the FDA “recall” news; representing a hit of some $1.5 billion from its market cap.
Its shares are still up about 50% in the past year.
Despite the recall, Edwards is on track toward its sales goals for the year.
It reported TAVR sales climbed 16% to $678 million for the second quarter ended June 30.
It boosted 2019 forecast for companywide sales to rise around the top end of its prior 9% to 12% range. It also raised its full-year adjusted earnings per share from $5.10 to $5.35 to $5.20 to $5.40.
